According to the company, esophageal cancer affects more than 600,000 people each year worldwide. It has a five-year survival rate of 20 per cent due to its late stage-diagnosis.

Proteomics says the prevalence of esophageal adenocarcinoma has increased drastically, recording a six-fold increase in the past 40 years. Some 90 per cent of esophageal adenocarcinoma cases go undetected despite between one per cent and two per cent of the western population considered to be at risk of developing the form of the disease.

The company will this week showcase its potentially game-changing findings at the 20th annual ISDE World Congress for Esophageal Diseases in Edinburgh, Scotland.

Proteomics’ fight against esophageal cancer appears to be gaining momentum, with the latest clinical studies showing how its simple blood test could potentially revolutionise the norms for the identification and treatment of one of the world’s most impactful diseases.

It is likely to mean that stock market participants will be keeping a close eye on the company as its commercialisation push for PromarkerEso builds steam.

Is your ASX-listed company doing something interesting? Contact: [email protected]